Subtopic Deep Dive
Blood-Brain Barrier Disruption in Metastases
Research Guide
What is Blood-Brain Barrier Disruption in Metastases?
Blood-Brain Barrier Disruption in Metastases studies pharmacological and physical methods to increase drug permeability across the compromised blood-tumor barrier in brain metastases from cancers like breast and lung.
Preclinical models quantify heterogeneous BTB permeability in breast cancer brain metastases (Lockman et al., 2010, 668 citations). Clinical trials test bevacizumab to normalize vascular permeability in glioblastoma, relevant to metastatic contexts (Kreisl et al., 2008, 1555 citations). Over 20 studies since 2010 analyze radiation and antibody-drug conjugates exploiting BBB disruptions.
Why It Matters
Heterogeneous BTB permeability limits chemotherapy efficacy in breast cancer brain metastases, as shown in Lockman et al. (2010) where drug delivery varied by lesion size. Bevacizumab improves progression-free survival in recurrent glioblastoma by altering vascular permeability (Kreisl et al., 2008). T-DM1 and trastuzumab deruxtecan demonstrate CNS penetration in HER2-positive metastases (Krop et al., 2014; Bartsch et al., 2022), enabling targeted therapies for 20-30% of breast cancer patients developing brain disease.
Key Research Challenges
Heterogeneous BTB Permeability
Drug delivery varies across metastases due to inconsistent barrier disruption (Lockman et al., 2010). Small lesions show intact BTB, limiting systemic therapy. Quantifying permeability requires advanced imaging.
Radiation-Induced Injury
Radiation disrupts BBB but causes cognitive decline in 100,000 US patients yearly (Greene-Schloesser et al., 2012). Balancing permeability gain against neurotoxicity remains unresolved. Dose optimization lacks consensus.
Drug Penetration Variability
Antibody-drug conjugates like T-DM1 show CNS activity but inconsistent efficacy (Krop et al., 2014). Genomic differences in metastases alter barrier function (Salhia et al., 2014). Predictive biomarkers are absent.
Essential Papers
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri Kreisl, Lyndon Kim, Kraig Moore et al. · 2008 · Journal of Clinical Oncology · 1.6K citations
Purpose To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma. Patients and Methods Patients with recurrent glioblastoma were treated with bevacizumab 10 mg/kg ev...
Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman, Rajendar K. Mittapalli, Kunal S. Taskar et al. · 2010 · Clinical Cancer Research · 668 citations
Abstract Purpose: Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten to compromise gains made in systemic chemotherapy. The blood–tum...
Radiation-induced brain injury: A review
Dana Greene-Schloesser, Mike E. Robbins, Ann M. Peiffer et al. · 2012 · Frontiers in Oncology · 664 citations
Approximately 100,000 primary and metastatic brain tumor patients/year in the US survive long enough (>6 months) to experience radiation-induced brain injury. Prior to 1970, the human brain was tho...
Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis
Bodour Salhia, Jeffrey Kiefer, Julianna T.D. Ross et al. · 2014 · PLoS ONE · 556 citations
The brain is a common site of metastatic disease in patients with breast cancer, which has few therapeutic options and dismal outcomes. The purpose of our study was to identify common and rare even...
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Burt Nabors, Jana Portnow, Manmeet S. Ahluwalia et al. · 2020 · Journal of the National Comprehensive Cancer Network · 531 citations
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain dise...
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
Riccardo Soffietti, Ufuk Abacıoğlu, Brigitta G. Baumert et al. · 2016 · Neuro-Oncology · 487 citations
The management of patients with brain metastases has become a major issue due to the increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, the European Associat...
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
Ian E. Krop, Nancy U. Lin, Kimberly Blackwell et al. · 2014 · Annals of Oncology · 396 citations
Reading Guide
Foundational Papers
Start with Lockman et al. (2010) for BTB heterogeneity in breast metastases; Kreisl et al. (2008) for bevacizumab vascular effects; Greene-Schloesser et al. (2012) for radiation disruption mechanisms.
Recent Advances
Bartsch et al. (2022) on trastuzumab deruxtecan CNS efficacy; Nabors et al. (2020) NCCN guidelines; Cacho-Díaz et al. (2020) on TME differences in metastases.
Core Methods
Evans Blue dye for permeability measurement (Lockman et al., 2010); MRI contrast enhancement for clinical assessment (Kreisl et al., 2008); genomic profiling of barrier genes (Salhia et al., 2014).
How PapersFlow Helps You Research Blood-Brain Barrier Disruption in Metastases
Discover & Search
Research Agent uses citationGraph on Lockman et al. (2010) to map 668-cited BTB studies, then findSimilarPapers reveals 50+ permeability papers. exaSearch queries 'blood-tumor barrier breast cancer metastases' for preclinical models. searchPapers filters by 'focused ultrasound BBB disruption metastases' for emerging trials.
Analyze & Verify
Analysis Agent runs readPaperContent on Lockman et al. (2010) to extract permeability data, then runPythonAnalysis with pandas plots drug AUC ratios across lesion sizes. verifyResponse (CoVe) grades bevacizumab claims from Kreisl et al. (2008) against NCCN guidelines (Nabors et al., 2020). GRADE scoring flags low-evidence radiation injury risks (Greene-Schloesser et al., 2012).
Synthesize & Write
Synthesis Agent detects gaps in BTB quantification post-2020 via gap detection on 250+ papers. Writing Agent uses latexSyncCitations to compile Lockman (2010) and Bartsch (2022) into a review, latexCompile generates figures, and exportMermaid diagrams citation networks from Kreisl (2008).
Use Cases
"Analyze permeability data from Lockman 2010 and plot drug delivery heterogeneity"
Research Agent → searchPapers('Lockman BTB') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot AUC vs lesion size) → matplotlib graph of delivery variability.
"Draft LaTeX review on BBB disruption therapies for breast cancer metastases"
Synthesis Agent → gap detection → Writing Agent → latexEditText(structure sections) → latexSyncCitations(Lockman 2010, Krop 2014) → latexCompile → PDF with synced references.
"Find code for BTB permeability simulations in metastases papers"
Research Agent → searchPapers('BTB permeability model code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → exportCsv of simulation scripts for radiation effects.
Automated Workflows
Deep Research workflow scans 50+ BTB papers: searchPapers → citationGraph(Kreisl 2008) → GRADE all claims → structured report on permeability trends. DeepScan applies 7-step CoVe to verify Lockman (2010) data against Salhia (2014) genomics. Theorizer generates hypotheses on ultrasound-enhanced delivery from EANO guidelines (Soffietti et al., 2016).
Frequently Asked Questions
What defines Blood-Brain Barrier Disruption in Metastases?
Compromised blood-tumor barrier enables variable drug delivery in brain metastases, quantified in breast cancer models (Lockman et al., 2010).
What methods enhance BBB permeability?
Bevacizumab normalizes vessels (Kreisl et al., 2008); radiation temporarily disrupts BBB (Greene-Schloesser et al., 2012); T-DM1 crosses for HER2 metastases (Krop et al., 2014).
What are key papers?
Lockman et al. (2010, 668 citations) on BTB heterogeneity; Kreisl et al. (2008, 1555 citations) on bevacizumab; Bartsch et al. (2022) on trastuzumab deruxtecan.
What open problems exist?
Predicting lesion-specific permeability; minimizing radiation neurotoxicity; biomarkers for drug penetration (Salhia et al., 2014; Nabors et al., 2020).
Research Brain Metastases and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Blood-Brain Barrier Disruption in Metastases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Brain Metastases and Treatment Research Guide